There is no Zepbound pill, and there is no Mounjaro pill. Tirzepatide — the medicine in both — is sold in the United States only as an injection. The search for a "Zepbound pill" usually lands on one of three real things instead: Eli Lilly's own weight-loss tablet, which contains a different drug; the semaglutide tablets made by Novo Nordisk; or unapproved "oral tirzepatide" products sold online. This page separates them, using FDA's product register, the labels and the trial registry, all read on 4 October 2026.
What FDA lists for tirzepatide
| Brand | Listed products | Forms | Route |
|---|---|---|---|
| Mounjaro | 24 | single-dose pen (6), single-dose vial (6), multi-dose vial (6), KwikPen (6) | subcutaneous |
| Zepbound | 24 | single-dose pen (6), single-dose vial (6), multi-dose vial (6), KwikPen (6) | subcutaneous |
| Any oral tirzepatide | 0 | — | — |
FDA Orange Book product file dated 11 September 2026; every one of the 48 entries is described as "solution; subcutaneous". Device names from the How Supplied section of each label. The newest entries are the KwikPens added in January 2026; the device record is on the Zepbound KwikPen.
The pill Lilly does sell: Foundayo
Lilly's oral GLP-1 drug is Foundayo, approved on 1 April 2026 (NDA 220934) in six tablet strengths. Its active ingredient is orforglipron, and that is the whole difference:
| Zepbound / Mounjaro | Foundayo | |
|---|---|---|
| Molecule | tirzepatide | orforglipron |
| Type | peptide (built on the GIP sequence) | small, non-peptide molecule |
| Molecular weight | 4,813 g/mol | 883 g/mol |
| Receptors | GIP and GLP-1 | GLP-1 only |
| How taken | weekly injection | daily tablet |
| Approved for | weight management, sleep apnoea (Zepbound); type 2 diabetes (Mounjaro) | weight management |
Molecular weights from PubChem; approval dates from FDA's Orange Book; receptors and use from the current labels.
So Foundayo is not "Zepbound in a pill". It is a separate drug, also made by Eli Lilly, with its own trials, its own side-effect table and its own price. How the two compare on results is on orforglipron vs tirzepatide; what the trial registry and label show about Foundayo itself is on the Foundayo review, and its price on what Foundayo costs.
Why tirzepatide is injected
The labels do not explain a company's formulation choices, and Lilly has published no reason. What the record does show is the obstacle any peptide faces when swallowed. Tirzepatide is a peptide — a chain of amino acids built on the sequence of the gut hormone GIP, according to its label — and the gut digests such chains. The only oral peptide GLP-1 sold in the US, semaglutide, gets around this with an absorption enhancer called SNAC — and even so, its label puts the share of the swallowed dose that reaches the bloodstream at about 0.4–1% for Rybelsus and 1–2% for the Ozempic tablets. Tirzepatide is about 17% heavier than semaglutide (4,813 against 4,114 g/mol). The two chemical routes to an oral GLP-1 drug — carry the peptide past the stomach, or replace it with a small molecule — are set out on oral GLP-1s. Lilly's pill took the second route.
Is an oral tirzepatide in development?
Not on the public record from Lilly. A search of ClinicalTrials.gov on 4 October 2026 for tirzepatide studies whose interventions mention a tablet, capsule or oral form found no Lilly study of tirzepatide by mouth, and a search for the phrase "oral tirzepatide" returned no studies at all.
One small trial comes close. NCT06648031, a phase 1b study run by Lexaria Bioscience (an oral drug-delivery company), enrolled 148 people between December 2024 and July 2025 and included an arm labelled "DehydraTECH Tirzepatide" alongside oral semaglutide arms and a Rybelsus control. The registry lists the tirzepatide arm's doses but gives it no route or dosage form, and no results have been posted. It is a single early study by a company testing its own delivery technology, not a product.
"Oral tirzepatide" sold online
Tablets, capsules, dissolving strips and "sublingual drops" labelled as tirzepatide are advertised online, often through telehealth sites or research-chemical shops. None appears in FDA's register of approved products, and no published study shows how much tirzepatide, if any, such a product delivers into the blood. FDA's position, on its page about unapproved GLP-1 drugs (content current as of 1 October 2026), is that unapproved versions of these drugs, "including semaglutide and tirzepatide", are risky because they "do not undergo FDA's review for safety, effectiveness and quality before they are marketed". The wider record on compounded products is on how compounded products differ from the approved drug.
If the question is "a GLP-1 I can swallow"
The approved oral options in October 2026 are Foundayo (orforglipron) and three semaglutide tablets — the Wegovy tablet, the Ozempic tablet and Rybelsus. The semaglutide tablets are covered on the Ozempic pill and the Wegovy pill review, and the two weight-loss pills side by side on Foundayo vs the Wegovy pill. Which, if any, suits a particular person is a decision for a prescriber; the labels set different daily rules for each, and they are not interchangeable with each other or with the injections.
Sources
FDA Orange Book data files, file date 11 September 2026, read 4 October 2026 · current labels for Rybelsus and Ozempic tablets (2026-01-30), Zepbound (2026-08-28), Mounjaro (2026-07-29) and Foundayo (2026-07-29), via openFDA · PubChem compound records for tirzepatide (CID 166567236), semaglutide (CID 56843331) and orforglipron (CID 137319706) · ClinicalTrials.gov searches and record NCT06648031 · FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, content current as of 1 October 2026. All read 4 October 2026.